APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenza Diagnostics

Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR).

Selected research

Market Outlook & Growth Opportunities

Global Influenza Diagnostics Market Outlook and Growth Opportunities 2026

Report ID 173894530422 December 2025197 pages

Choose your research edition.

Industry ResearchInfluenza Diagnostics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Diagnostics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Influenza Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Diagnostics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Diagnostics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR).

North America is the largest consumption place, with a consumption marker share nearly 53%. Following North America, Europe is the second largest consumption place with the consumption market share of 25%.

The main manufacturers are BD, Abbott (Include Alere), Roche, SIEMENS, Analytik Jena, Quidel, Thermo Fisher, Meridian Bioscience, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific etc. BD is the largest manufacturer with about 19% market share.

Read the full market overview

This report provides an overview of the global Influenza Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Influenza Diagnostics market.

Influenza Diagnostics Segment by Company

BD

Abbott (Include Alere)

Roche

SIEMENS

Analytik Jena

Quidel

Thermo Fisher

Meridian Bioscience

BioMerieux

Sekisui Diagnostics

Response Biomedical

SA Scientific

Influenza Diagnostics Segment by Type

RIDT

RT-PCR

Cell Culture

Others

Influenza Diagnostics Segment by Application

Hospitals

POCT

Others

Influenza Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Influenza Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Influenza Diagnostics key companies, revenue, market share, and recent developments.

3. To split the Influenza Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Influenza Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Diagnostics industry.

Chapter 3: Detailed analysis of Influenza Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Influenza Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Influenza Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza Diagnostics Industry Trends Table 2. Influenza Diagnostics Industry Drivers Table 3. Influenza Diagnostics Industry Opportunities and Challenges Table 4. Influenza Diagnostics Industry Restraints Table 5. Global Influenza Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza Diagnostics Revenue Share by Company (2021-2026) Table 7. Global Influenza Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Influenza Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global Influenza Diagnostics Company, Product Type & Application Table 10. Global Influenza Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Influenza Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of RIDT Table 15. Significant Companies of RT-PCR Table 16. Significant Companies of Cell Culture Table 17. Significant Companies of Others Table 18. Global Influenza Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Influenza Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Influenza Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Influenza Diagnostics Sales Value Share by Type (2021-2026) Table 22. Global Influenza Diagnostics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of POCT Table 25. Significant Companies of Others Table 26. Global Influenza Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Influenza Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Influenza Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Influenza Diagnostics Sales Value Share by Application (2021-2026) Table 30. Global Influenza Diagnostics Sales Value Share by Application (2027-2032) Table 31. Global Influenza Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Influenza Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Influenza Diagnostics Sales Value Share by Region (2021-2026) Table 34. Global Influenza Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Influenza Diagnostics Sales Value Share by Region (2027-2032) Table 36. Global Influenza Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Influenza Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Influenza Diagnostics Sales Value Market Share by Country (2021-2026) Table 39. Global Influenza Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Influenza Diagnostics Sales Value Market Share by Country (2027-2032) Table 41. BD Company Information Table 42. BD Business Overview Table 43. BD Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. BD Influenza Diagnostics Product Portfolio Table 45. BD Recent Development Table 46. Abbott (Include Alere) Company Information Table 47. Abbott (Include Alere) Business Overview Table 48. Abbott (Include Alere) Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abbott (Include Alere) Influenza Diagnostics Product Portfolio Table 50. Abbott (Include Alere) Recent Development Table 51. Roche Company Information Table 52. Roche Business Overview Table 53. Roche Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Roche Influenza Diagnostics Product Portfolio Table 55. Roche Recent Development Table 56. SIEMENS Company Information Table 57. SIEMENS Business Overview Table 58. SIEMENS Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. SIEMENS Influenza Diagnostics Product Portfolio Table 60. SIEMENS Recent Development Table 61. Analytik Jena Company Information Table 62. Analytik Jena Business Overview Table 63. Analytik Jena Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Analytik Jena Influenza Diagnostics Product Portfolio Table 65. Analytik Jena Recent Development Table 66. Quidel Company Information Table 67. Quidel Business Overview Table 68. Quidel Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Quidel Influenza Diagnostics Product Portfolio Table 70. Quidel Recent Development Table 71. Thermo Fisher Company Information Table 72. Thermo Fisher Business Overview Table 73. Thermo Fisher Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Thermo Fisher Influenza Diagnostics Product Portfolio Table 75. Thermo Fisher Recent Development Table 76. Meridian Bioscience Company Information Table 77. Meridian Bioscience Business Overview Table 78. Meridian Bioscience Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Meridian Bioscience Influenza Diagnostics Product Portfolio Table 80. Meridian Bioscience Recent Development Table 81. BioMerieux Company Information Table 82. BioMerieux Business Overview Table 83. BioMerieux Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. BioMerieux Influenza Diagnostics Product Portfolio Table 85. BioMerieux Recent Development Table 86. Sekisui Diagnostics Company Information Table 87. Sekisui Diagnostics Business Overview Table 88. Sekisui Diagnostics Influenza Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sekisui Diagnostics Influenza Diagnostics Product Portfolio Table 90. Sekisui Diagnostics Recent Development Table 91. Response Biomedical Company Information Table 92. Response Biomedical Business Overview Table 93. Response Biomedical Influenza Diagnostics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 94. Response Biomedical Influenza Diagnostics Product Portfolio Table 95. Response Biomedical Recent Development Table 96. SA Scientific Company Information Table 97. SA Scientific Business Overview Table 98. SA Scientific Influenza Diagnostics Sales (), Value (US$ Million), Price () and Gross Margin (2021-2026) Table 99. SA Scientific Influenza Diagnostics Product Portfolio Table 100. SA Scientific Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Influenza Diagnostics Product Image Figure 2. Global Influenza Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. RIDT Image Figure 8. RT-PCR Image Figure 9. Cell Culture Image Figure 10. Others Image Figure 11. Global Influenza Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Influenza Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Influenza Diagnostics Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. POCT Image Figure 16. Others Image Figure 17. Global Influenza Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Influenza Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Influenza Diagnostics Sales Value Share by Application (2021-2032) Figure 20. Global Influenza Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Influenza Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Influenza Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Influenza Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Influenza Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Influenza Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Influenza Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Influenza Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Influenza Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Influenza Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Influenza Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Influenza Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Influenza Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • RIDT
  • RT-PCR
  • Cell Culture
  • Others
Applications
  • Hospitals
  • POCT
  • Others
Companies covered
  • BD
  • Abbott (Include Alere)
  • Roche
  • SIEMENS
  • Analytik Jena
  • Quidel
  • Thermo Fisher
  • Meridian Bioscience
  • BioMerieux
  • Sekisui Diagnostics
  • Response Biomedical
  • SA Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenza Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenza Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Influenza Diagnostics Market Dynamics
  1. 2.1 Influenza Diagnostics Industry Trends
  2. 2.2 Influenza Diagnostics Industry Drivers
  3. 2.3 Influenza Diagnostics Industry Opportunities and Challenges
  4. 2.4 Influenza Diagnostics Industry Restraints
3 Influenza Diagnostics Market by Company
  1. 3.1 Global Influenza Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global Influenza Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global Influenza Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global Influenza Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global Influenza Diagnostics Company Product Type and Application
  6. 3.6 Global Influenza Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Influenza Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Influenza Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Influenza Diagnostics Market by Type
  1. 4.1 Influenza Diagnostics Type Introduction
  2. 4.1.1 RIDT
  3. 4.1.2 RT-PCR
  4. 4.1.3 Cell Culture
  5. 4.1.4 Others
  6. 4.2 Global Influenza Diagnostics Sales Value by Type
  7. 4.2.1 Global Influenza Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Influenza Diagnostics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Influenza Diagnostics Sales Value Share by Type (2021-2032)
5 Influenza Diagnostics Market by Application
  1. 5.1 Influenza Diagnostics Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 POCT
  4. 5.1.3 Others
  5. 5.2 Global Influenza Diagnostics Sales Value by Application
  6. 5.2.1 Global Influenza Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza Diagnostics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Influenza Diagnostics Sales Value Share by Application (2021-2032)
6 Influenza Diagnostics Regional Value Analysis
  1. 6.1 Global Influenza Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Influenza Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Influenza Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenza Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America Influenza Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Influenza Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe Influenza Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Influenza Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Influenza Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Influenza Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America Influenza Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Influenza Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Influenza Diagnostics Sales Value Share by Country, 2025 VS 2032
7 Influenza Diagnostics Country-level Value Analysis
  1. 7.1 Global Influenza Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Influenza Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Influenza Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Influenza Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Influenza Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Influenza Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BD
  2. 8.1.1 BD Company Information
  3. 8.1.2 BD Business Overview
  4. 8.1.3 BD Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BD Influenza Diagnostics Product Portfolio
  6. 8.1.5 BD Recent Developments
  7. 8.2 Abbott (Include Alere)
  8. 8.2.1 Abbott (Include Alere) Company Information
  9. 8.2.2 Abbott (Include Alere) Business Overview
  10. 8.2.3 Abbott (Include Alere) Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abbott (Include Alere) Influenza Diagnostics Product Portfolio
  12. 8.2.5 Abbott (Include Alere) Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Influenza Diagnostics Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 SIEMENS
  20. 8.4.1 SIEMENS Company Information
  21. 8.4.2 SIEMENS Business Overview
  22. 8.4.3 SIEMENS Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SIEMENS Influenza Diagnostics Product Portfolio
  24. 8.4.5 SIEMENS Recent Developments
  25. 8.5 Analytik Jena
  26. 8.5.1 Analytik Jena Company Information
  27. 8.5.2 Analytik Jena Business Overview
  28. 8.5.3 Analytik Jena Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Analytik Jena Influenza Diagnostics Product Portfolio
  30. 8.5.5 Analytik Jena Recent Developments
  31. 8.6 Quidel
  32. 8.6.1 Quidel Company Information
  33. 8.6.2 Quidel Business Overview
  34. 8.6.3 Quidel Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Quidel Influenza Diagnostics Product Portfolio
  36. 8.6.5 Quidel Recent Developments
  37. 8.7 Thermo Fisher
  38. 8.7.1 Thermo Fisher Company Information
  39. 8.7.2 Thermo Fisher Business Overview
  40. 8.7.3 Thermo Fisher Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Thermo Fisher Influenza Diagnostics Product Portfolio
  42. 8.7.5 Thermo Fisher Recent Developments
  43. 8.8 Meridian Bioscience
  44. 8.8.1 Meridian Bioscience Company Information
  45. 8.8.2 Meridian Bioscience Business Overview
  46. 8.8.3 Meridian Bioscience Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Meridian Bioscience Influenza Diagnostics Product Portfolio
  48. 8.8.5 Meridian Bioscience Recent Developments
  49. 8.9 BioMerieux
  50. 8.9.1 BioMerieux Company Information
  51. 8.9.2 BioMerieux Business Overview
  52. 8.9.3 BioMerieux Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioMerieux Influenza Diagnostics Product Portfolio
  54. 8.9.5 BioMerieux Recent Developments
  55. 8.10 Sekisui Diagnostics
  56. 8.10.1 Sekisui Diagnostics Company Information
  57. 8.10.2 Sekisui Diagnostics Business Overview
  58. 8.10.3 Sekisui Diagnostics Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sekisui Diagnostics Influenza Diagnostics Product Portfolio
  60. 8.10.5 Sekisui Diagnostics Recent Developments
  61. 8.11 Response Biomedical
  62. 8.11.1 Response Biomedical Company Information
  63. 8.11.2 Response Biomedical Business Overview
  64. 8.11.3 Response Biomedical Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Response Biomedical Influenza Diagnostics Product Portfolio
  66. 8.11.5 Response Biomedical Recent Developments
  67. 8.12 SA Scientific
  68. 8.12.1 SA Scientific Company Information
  69. 8.12.2 SA Scientific Business Overview
  70. 8.12.3 SA Scientific Influenza Diagnostics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 SA Scientific Influenza Diagnostics Product Portfolio
  72. 8.12.5 SA Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst